Fosinopril

Angiotensin Converting Enzyme Inhibitor — CARDIOVASCULAR SYSTEM

Key facts

Fosinopril is an ofp drug in the Angiotensin Converting Enzyme Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1991. Its mechanism of action is classified as Angiotensin-converting Enzyme Inhibitors. DrugCentral lists 2 molecular targets, including ACE and ACE. Recorded indications include Chronic heart failure and Hypertensive disorder.

• Approval status: ofp (first approved 1991 by the FDA).
• Drug class: Angiotensin Converting Enzyme Inhibitor.
• Mechanism of action: Angiotensin-converting Enzyme Inhibitors.
• Molecular targets: ACE and ACE (2 listed in DrugCentral).
• Indications: Chronic heart failure and Hypertensive disorder.
• ATC code: C09AA09 (ACE inhibitors, plain).
• Molecular formula: C30H46NO7P; molecular weight 563.67 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Chronic heart failure
• Hypertensive disorder

Off-label uses (6)

• Acute scleroderma renal crisis
• Atrial fibrillation
• Diabetic renal disease
• Diastolic heart failure
• Hypertension due to Scleroderma
• Nondiabetic Proteinuric Nephropathy

Contraindications (37)

• Acute cerebrovascular insufficiency
• Acute pancreatitis
• Angioedema
• Anuria
• Aortic valve stenosis
• Azotemia
• Bone marrow depression
• Dehydration
• Diabetes mellitus
• Disease of liver
• Disorder of connective tissue
• Gout
• Hemodialysis with High-Flux Membrane
• Hepatic coma
• Hereditary angioneurotic edema
• Hypercalcemia
• Hypercholesterolemia
• Hyperkalemia
• Hyperparathyroidism
• Hypertrophic cardiomyopathy
• Hyperuricemia
• Hypochloremic alkalosis
• Hypokalemia
• Hypomagnesemia
• Hyponatremia
• Hypovolemia
• Immunosuppression
• Kidney disease
• Low blood pressure
• Neonatal hyperbilirubinemia
• + 7 more

Mechanism & targets

• Mechanism of action (MoA): Angiotensin-converting Enzyme Inhibitors
• Established pharmacologic class: Angiotensin Converting Enzyme Inhibitor

Molecular targets (2)

Target	Gene	Action	Activity
Angiotensin-converting enzyme	ACE	inhibitor	IC50 9.00
Angiotensin-converting enzyme	ACE	unknown	Ki 8.82

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1991-05-16	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
C09AA09	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, PLAIN › ACE inhibitors, plain
C09BA09	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, COMBINATIONS › ACE inhibitors and diuretics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Angioedema	216.1
Acute kidney injury	174.8
Cardiac failure congestive	167.6
Myocardial infarction	145.0
Bradycardia	124.6
Hyperkalaemia	103.6
Hypoglycaemia	72.3
Rhabdomyolysis	68.6
Coronary artery disease	64.7
Cerebrovascular accident	61.5
Treatment noncompliance	61.1
International normalised ratio increased	59.8

Chemical structure

• Molecular formula: C₃₀H₄₆NO₇P
• Molecular weight: 563.67 g/mol
• CAS number: 98048-97-6
• InChIKey: BIDNLKIUORFRQP-XYGFDPSESA-N
• PubChem CID: 62956

CCC(=O)O[C@@H](O[P@](=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Fosinopril used for?

DrugCentral lists the following indications for Fosinopril: Chronic heart failure and Hypertensive disorder.

How does Fosinopril work?

Fosinopril is classified as Angiotensin-converting Enzyme Inhibitors; its molecular targets in DrugCentral include ACE (inhibitor) and ACE.

When was Fosinopril first approved?

Fosinopril was first approved by the FDA in 1991.

What drug class does Fosinopril belong to?

Fosinopril is in the Angiotensin Converting Enzyme Inhibitor class.

What is the chemical formula of Fosinopril?

Fosinopril has the molecular formula C30H46NO7P and a molecular weight of 563.67 g/mol.

Sources

• DrugCentral drug card 1245 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3039596 — compound record and bioactivity
• PubChem CID 62956 — chemical identifiers
• DrugBank DB00492 — drug record
• FDA UNII R43D2573WO — substance identity
• DailyMed: FDA labels for Fosinopril — current prescribing information (label search)
• UniProt P12821 (ACE) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.